engleski

Ergogenic potential and risks of recombinant human erythropoietin (rhEPO) misuse in sport

Recombinant human erythropoietin (rhEpo) is a erythropoietic agent being used worldwide mainly in the treatment of patients with anemia of chronic kidney disease and in patients with malignant disease whose anemia is caused by chemotherapy. Unfortunatelly, it has been misused in sport, however atheltes who misuse rhEpo tend to consider only the benefits to performance, while ignoring the potential risks of rhEpo abuse. While any potential adverse effect is unacceptable in healthy population, we emphasise the fact that use of rhEpo can lead to fatal outcomes with main risks being that of fatal thrombotic events, sudden death and a rare, but potentially devastating risk of aplastic anemia. Therefore, both athletes and medical doctors who encounter and inform them should be aware of possible adverse effects of rhEpo use.

recombinant human erythropoietin; adverse effect; sport; doping

nije evidentirano